Asset profile
Apatinib
Small molecule
Phase 3underway
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. The registry's posted readout date (2023-12) has passed without a status update. Check News for topline announcements.
NCT01270386: This was a randomized, quadruple-blinded, placebo-controlled trial with 136 patients and progression-free survival as the primary endpoint. Apatinib significantly extended progression-free survival compared with placebo (median 4.7 vs 1.9 months), with higher response and disease-control rates as well.
Primary data exist only as an ASCO 2012 conference abstract; figures are quoted from a peer-reviewed pooled analysis citing that abstract.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Apatinib: this drug | Phase 3 | Small molecule | VEGFR2 | ||
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(77 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (12)
October 2026 (2)
November 2026 (1)
December 2026 (9)
Phase 2Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase InhibitorNot yet recruiting
Est. primary completion 2026-12 · NCT06538935 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TreatmentRecruiting
Est. primary completion 2026-12 · NCT06576973 · CT.gov ↗
What to watch
Phase 2Carcinoma, HepatocellularRecruiting
Est. primary completion 2026-12 · NCT06454578 · CT.gov ↗
What to watch
Phase 2Unresectable Biliary Tract CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06749730 · CT.gov ↗
What to watch
Phase 2/3Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04208347 · CT.gov ↗
What to watch
Phase 2Gestational Trophoblastic NeoplasiaRecruiting
Est. primary completion 2026-12-01 · NCT05139095 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Limited StageRecruiting
Est. primary completion 2026-12-01 · NCT06483282 · CT.gov ↗
What to watch
Phase 2Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06831175 · CT.gov ↗
What to watch
Phase 2Digestive System CancersRecruiting
Est. primary completion 2026-12-31 · NCT06099821 · CT.gov ↗
What to watch
2027 (37)
January 2027 (1)
Phase 2Metastatic Pancreatic CarcinomaNot yet recruiting
Est. primary completion 2027-01-15 · NCT06759090 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-01 · NCT07031154 · CT.gov ↗
What to watch
Phase 2Advanced Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
Phase 3Advanced Breast Cancer, HR+/HER2- Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT06447623 · CT.gov ↗
What to watch
March 2027 (5)
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-03-01 · NCT06296563 · CT.gov ↗
What to watch
Phase 1/2Osteosarcoma, Osteosarcoma MetastaticRecruiting
Est. primary completion 2027-03-05 · NCT07479732 · CT.gov ↗
What to watch
Phase 2Unresectable Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
Phase 2Resectable Intrahepatic Cholangiocarcinoma With High Risk of RecurrenceRecruiting
Est. primary completion 2027-03-31 · NCT06280508 · CT.gov ↗
What to watch
Early phase / not applicableHCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-03-31 · NCT07618546 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Solid TumorNot yet recruiting
Est. primary completion 2027-04-01 · NCT06537505 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06385873 · CT.gov ↗
What to watch
Phase 2AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06973330 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Hepatocellular Carcinoma Non-resectableNot yet recruiting
Est. primary completion 2027-06 · NCT07192848 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Recruiting
Est. primary completion 2027-06-01 · NCT06925516 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-06-20 · NCT07033819 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Biliary Tract Cancer (CCA)Recruiting
Est. primary completion 2027-06-30 · NCT07135544 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskNot yet recruiting
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch
Phase 2Advanced Gastric Cancer, SHR1701Recruiting
Est. primary completion 2027-07-15 · NCT07294664 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Extensive StageNot yet recruiting
Est. primary completion 2027-07-25 · NCT06786312 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Gastric Cancer, Apatinib, BiomarkerRecruiting
Est. primary completion 2027-08 · NCT03219593 · CT.gov ↗
What to watch
Phase 2Mixed Hepatocellular-cholangiocarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07105748 · CT.gov ↗
What to watch
Phase 3Gastric Cancer, SurgeryNot yet recruiting
Est. primary completion 2027-08-25 · NCT07314203 · CT.gov ↗
What to watch
Phase 2Gastrointestinal Stromal TumorsRecruiting
Est. primary completion 2027-08-31 · NCT05905887 · CT.gov ↗
What to watch
September 2027 (2)
December 2027 (12)
Phase 2Small Cell Lung Cancer Extensive StageRecruiting
Est. primary completion 2027-12 · NCT06749691 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular Carcinoma(HCC)Recruiting
Est. primary completion 2027-12-15 · NCT06893887 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07773363 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer AdultNot yet recruiting
Est. primary completion 2027-12-31 · NCT07314372 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-12-31 · NCT07154082 · CT.gov ↗
What to watch
Phase 2Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2027-12-31 · NCT06764368 · CT.gov ↗
What to watch
Phase 2Mucosal MelanomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07236528 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
Phase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR …Recruiting
Est. primary completion 2027-12-31 · NCT06925243 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Gastric CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07371871 · CT.gov ↗
What to watch
2028 (17)
January 2028 (2)
Phase 2Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug RepurposingNot yet recruiting
Est. primary completion 2028-01-01 · NCT07324473 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (GC), Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-01-01 · NCT07311408 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (1)
Phase 2Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-03-01 · NCT06339619 · CT.gov ↗
What to watch
May 2028 (2)
July 2028 (3)
Phase 2Advanced Unresectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-07 · NCT07749859 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 3BCLC Stage C Hepatocellular Carcinoma, Chemotherapy EffectRecruiting
Est. primary completion 2028-07-31 · NCT06172205 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Limited-stage Small Cell Lung Cancer (LS-SCLC)Enrolling by invitation
Est. primary completion 2028-08-01 · NCT06773156 · CT.gov ↗
What to watch
September 2028 (2)
December 2028 (4)
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-12-30 · NCT07569679 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07610629 · CT.gov ↗
What to watch
Phase 3Breast Cancer Stage IV, Triple -Negative Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch
2029 (5)
February 2029 (1)
Phase 1Biliary Tract MalignanciesRecruiting
Est. primary completion 2029-02-23 · NCT06181032 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Recurrent/Metastatic Endometrial CancerNot yet recruiting
Est. primary completion 2029-04-01 · NCT06771154 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 PositiveNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Hepato Cellular Carcinoma (HCC), Chemotherapy EffectRecruiting
Est. primary completion 2029-10 · NCT07267806 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1/2Liver CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07587034 · CT.gov ↗
What to watch
2030 (4)
June 2030 (1)
Phase 2Stomach NeoplasmsActive not recruiting
Est. primary completion 2030-06 · NCT02485015 · CT.gov ↗
What to watch
July 2030 (2)
December 2030 (1)
Phase 2/3Unresectable Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2030-12-31 · NCT06739317 · CT.gov ↗
What to watch
2031 (2)
March 2031 (2)
Phase 3Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast CancerRecruiting
Est. primary completion 2031-03 · NCT06255392 · CT.gov ↗
What to watch
Phase 3Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast CancerActive not recruiting
Est. primary completion 2031-03 · NCT07371910 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.